Unicycive Therapeutics (UNCY) Change in Accured Expenses (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Change in Accured Expenses data on file, last reported at $2.3 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 188.87% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 233.2% YoY) and the FY2025 annual result came in at -$2.5 million, down 417.09% from the prior year.
• Change in Accured Expenses improved to $2.3 million in Q1 2026, from -$1.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q1 2026 to a low of -$2.3 million in Q2 2025.
• A 5-year average of $183117.6 and a median of $24000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 904.17% — and 2024, when it jumped 525.91%.
• Tracing UNCY's Change in Accured Expenses over 5 years: stood at -$641000.0 in 2022, then jumped by 166.61% to $427000.0 in 2023, then jumped by 127.4% to $971000.0 in 2024, then plunged by 286.82% to -$1.8 million in 2025, then soared by 225.96% to $2.3 million in 2026.
• The last three Change in Accured Expenses figures came in at $2.3 million (Q1 2026), -$1.8 million (Q4 2025), and $775000.0 (Q3 2025), per Business Quant data.